Location History:
- Seattle, WA (US) (1986)
- Redmond, WA (US) (1989 - 2003)
Company Filing History:
Years Active: 1986-2003
Title: An Overview of Inventor Steven K Dower from Redmond, WA
Introduction
Steven K Dower is a notable inventor based in Redmond, Washington. With an impressive portfolio of 17 patents, he has made significant contributions to the field of immunology and biotechnology. His innovative work has paved the way for advancements in understanding and utilizing interleukin-1 receptors.
Latest Patents
Dower's latest patents include a range of groundbreaking inventions. One notable patent is focused on Type II Interleukin-1 receptors, specifically Type II IL-1 receptor proteins, DNAs, and expression vectors that encode these receptors. This invention outlines processes for producing Type II IL-1R as products of recombinant cell culture.
Additionally, he has developed another significant patent relating to antibodies for interleukin-1 receptors. This invention features monoclonal antibodies and binding proteins that bind specifically to the IL-1 receptor. Moreover, it describes methods for detecting IL-1 receptors on cells and soluble IL-1 receptors in serum, which are crucial for various diagnostic applications.
Career Highlights
Steven K Dower has built a distinguished career at Immunex Corporation, where he plays a vital role in pioneering research and development in immunology. His extensive patent portfolio reflects his innovative mindset and expertise in creating valuable biomedical solutions that enhance our understanding of immune responses.
Collaborations
Throughout his career, Dower has collaborated with esteemed colleagues, including John Ernest Sims and Carl J March. These collaborations have resulted in fruitful research endeavors, further contributing to the field of immunology.
Conclusion
With his extensive patent portfolio and impactful contributions to the field of immunology, Steven K Dower stands out as a significant figure in modern biotechnology. His work at Immunex Corporation and collaborations with other experts continue to influence the direction of research and innovation in understanding interleukin-1 receptors.